Astellas Pharma Inc.
ALPMF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $2,627,222 | $3,037,526 | $3,449,584 | $3,487,859 |
| - Cash | $188,372 | $335,687 | $376,840 | $315,986 |
| + Debt | $831,426 | $1,005,716 | $200,007 | $212,744 |
| Enterprise Value | $3,270,276 | $3,707,555 | $3,272,751 | $3,384,617 |
| Revenue | $1,912,323 | $1,603,672 | $1,518,619 | $1,296,163 |
| % Growth | 19.2% | 5.6% | 17.2% | – |
| Gross Profit | $1,563,117 | $1,311,187 | $1,230,266 | $1,043,154 |
| % Margin | 81.7% | 81.8% | 81% | 80.5% |
| EBITDA | $248,046 | $194,814 | $337,390 | $297,829 |
| % Margin | 13% | 12.1% | 22.2% | 23% |
| Net Income | $50,747 | $17,045 | $98,714 | $124,086 |
| % Margin | 2.7% | 1.1% | 6.5% | 9.6% |
| EPS Diluted | 28.24 | 9.47 | 54.09 | 67.05 |
| % Growth | 198.2% | -82.5% | -19.3% | – |
| Operating Cash Flow | $194,512 | $172,475 | $327,767 | $257,444 |
| Capital Expenditures | -$57,330 | -$82,497 | -$88,541 | -$76,448 |
| Free Cash Flow | $137,182 | $89,978 | $239,226 | $180,996 |